Key result
Baroreflex activation therapy is discussed as a novel nonpharmacologic approach for the management of treatment-resistant hypertension.
Why the study?
Does baroreflex activation therapy improve outcomes in patients with treatment-resistant hypertension?
Does baroreflex activation therapy improve outcomes in patients with treatment-resistant hypertension?
This review discusses the potential role of baroreflex activation therapy as a nonpharmacologic treatment option for patients with resistant hypertension.
Baroreflex activation therapy remains investigational for resistant hypertension; leaves open its clinical role pending randomized outcome trials.
Hypertension (HTN) is a worldwide epidemic. When untreated, HTN places patients at an elevated risk for several health conditions, including cardiovascular disease and end-organ damage. This effect is particularly pronounced in a subset of patients who experience treatment-resistant HTN despite the utilization of conventional medication and lifestyle interventions. For these challenging patients, ongoing research efforts continue to explore and develop novel nonpharmacologic therapies for resistant HTN. One such avenue is the regulation of the sympathetic nervous system, a large component of circulatory physiology. Innovative therapies have evolved to harness the ability to deliver electrical stimulation to baroreceptors in an effort to modulate the sympathetic system involvement in HTN. This review discusses baroreflex activation therapy and its role in the management of resistant HTN.
No takes yet. Share an insight, caveat, or question.
Yoruk et al. (2016) conducted a review in Resistant hypertension. Baroreflex activation therapy was evaluated. Baroreflex activation therapy is discussed as a novel nonpharmacologic approach for the management of treatment-resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: